Activity Description:

Review all criteria for diagnosis, appropriate diagnostic methodology principals/ method of treatment for lung cancer. Describe the rational/ indications for new diagnosis/treatment methods and implications. Discussion to determine follow up treatment for patients with lung nodules greater than 8mm.

Target Audience:

Physicians - Medical Oncology, Radiology Oncology, Pathology, Surgery, Pulmonary, Thoracic Surgery

Learning Objectives:

By the end of this CME activity, participants should be better able to:

1. Identify ways to provide comprehensive care for lung tumor patients through a collaborative team effort.
2. Evaluate different specialty approaches to lung tumor treatment and care.
3. Implement best practices discussed in tumor board presentations. 
4. Identify and address issues of race, language and ethnic implications, including implicit bias, in lung cancer diagnosis, care and treatment.

Moderator:

Sanjay Khicia, MD

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.